Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial - Cortés, Jorge Eduardo; Krämer, Alwin (The lancet. Oncology, 2018)
Gesehen am 01.07.2019